This includes low prevalence biomarkers such as NTRK1, NTRK2, and NTRK3 (NTRK1/2/3) fusions as well as higher prevalence complex biomarkers such as tumor mutational burden-High (TMB-H). This evidence concerns the gene NTRK3 and neoplasm.